- Home
- WPP vs ACAD Comparison
WPP vs ACAD Comparison
Compare WPP & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WPP | ACAD |
|---|---|---|
| Founded | 1985 | 1993 |
| Country | United Kingdom | United States |
| Employees | 104000 | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.9B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | WPP | ACAD |
|---|---|---|
| Price | $16.72 | $21.69 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 22 |
| Target Price | N/A | ★ $30.55 |
| AVG Volume (30 Days) | 711.2K | ★ 1.7M |
| Earning Date | 04-24-2026 | 05-06-2026 |
| Dividend Yield | ★ 12.77% | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | N/A | ★ 2.30 |
| Revenue | N/A | ★ $726,437,000.00 |
| Revenue This Year | N/A | $18.90 |
| Revenue Next Year | $4.33 | $11.62 |
| P/E Ratio | $38.96 | ★ $9.81 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $14.81 | $14.08 |
| 52 Week High | $40.95 | $28.35 |
Technical Indicators
Market Signals| Indicator | WPP | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 53.38 | 46.16 |
| Support Level | $15.89 | $21.51 |
| Resistance Level | $19.55 | $22.03 |
| Average True Range (ATR) | 0.46 | 0.72 |
| MACD | 0.28 | 0.19 |
| Stochastic Oscillator | 68.68 | 51.38 |
Price Performance
Historical ComparisonAbout WPP WPP plc
Headquartered in the United Kingdom, WPP is the world's largest ad holding company based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe. WPP is the largest media buying entity in the world.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.